A therapy mix including Bayer’s Nubeqa drug was shown to significantly prolong the lives of men suffering from metastatic prostate cancer in a clinical study, prompting the company to boost sales estimates for the product.
https://www.pharmalive.com/wp-content/uploads/2020/01/Bayer-Germany_Reuters_1-16-20_584W-Slider.jpeg387584Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-02-18 05:55:002022-02-18 14:37:22Bayer lifts peak sales estimate for prostate cancer drug